Easton Pharmaceuticals & Partner BMV Medica Announce Delivery and Launch of AmnioSense (AL-Sense) in Mexico; Delivery Date for Purchase Order From Windsor Pharmaceuticals for Central America
Published: Dec 06, 2017
TORONTO, ON, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Easton Pharmaceuticals (OTC: EAPH) and its JV partner, BMV Medica SA de CV, announces product delivery and launch of its licensed AmnioSense (AL-Sense) product from its previously announced Gedeon Richter distribution agreement for Mexico. Easton/BMV is also expecting delivery this week of initial Purchase Order for Central America with exclusive Distribution Partner, Windsor Pharmaceuticals, with launch in initial countries in Central America by February, 2018.
Per its previously announced sub-licensing agreement executed with Gedeon Richter SA de CV, a Mexican subsidiary of Gedeon Richter SA of Hungary, Easton / BMV have been notified that after delays on items including importation permits, AmnioSense has been delivered in Mexico and has launched in the Mexico market. In addition, after filing the regulatory documents subsequent to a signed sub-licensing agreement with Panama- based Windsor Pharmaceuticals, Easton and BMV Medica previously received confirmation that Windsor Pharmaceuticals received government regulatory approval to begin the marketing and selling of products “VS-Sense” and “AL-Sense” initially in Guatemala, with the other territories, - El Salvador, Honduras, Panama, Costa Rica, Nicaragua, and the Dominican Republic to follow shortly thereafter. After a 3 month period where product preparation, naming and packaging issues were resolved, product has been transported and is nearing delivery with official launch expected in February 2018.
The Central American and Caribbean region possesses a total population of over 50,000,000 where Windsor Pharmaceuticals SA has projected sales in excess of $3,000,000 in the second full year of launch for both of its licensed products “Al-Sense” and “VS-Sense”. Thereafter, market penetration increases and other products will be added. Focus group research with gynecologists in the region have indicated a strong demand for both products which coincides with growing global sales of these products, supporting the belief in the region that a company such as Windsor Pharmaceuticals SA with innovative specialty products can fill the current void in product offerings to the Obstetricians/Gynecologists. Sales are expected to commence in Q1 2018 now that the initial regulatory approval has been received. Orders for product have been placed with manufacturers slated for December delivery.
Mexico, with a birth rate of over 2 million annually Easton / BMV expect sales volumes of AmnioSense to increase rapidly over the course of the first year of launch for AmnioSense, a diagnostic which is able to differentiate between urine and amniotic fluid leaks in late pregnancy and allows pregnant women to avoid unnecessary trips to the hospital; or if the test is positive, an indication to go to the hospital confident that their “water broke” and it is time for delivery.
Gynofit – the natural treatment for BV (bacterial Vaginosis) has had initial and rollout delays post-launch due mostly to logistical issues, which since have been sorted out. Easton / BMV look forward to new Purchase Orders in early 2018 as sales are expected to ramp up from the initial $400,000 in purchase orders during the quarter ending June 30th.
In other news, Easton / BMV Medica can disclose that an upfront deposit payment towards a sub-distribution agreement for a third product launch has been received from a large multi-national pharmaceutical company possessing over 100,000 worldwide employees. A press release has been drafted and is awaiting legal approval for an anticipated release sometime this month.
VS-Sense (VagiSense): is the current brand name of the BV (Bacterial Vaginosis) patented diagnostic test, planned for launch in Mexico and other larger markets in Latin America, but may be renamed depending on the outcome of partner discussions with multi-national pharmaceutical companies, initiated in late 2015 and early 2016. VagiSense (VS-Sense) is the same product Bayer Pharmaceuticals had licensed and launched in late 2015 in Europe under its brand, Canestest, and with Prestige Distribution currently selling in the US under its brand, Monistat, with multi-million dollars in sales and growing.
AL-Sense (AmnioSense): patented amniotic fluid leak test now marketed in two presentations to capture maximum market, and is a unique Point-of-Care diagnostic panty liner for women in late-stage pregnancy able to distinguish between urine and amniotic fluid (breaking of water).
About Windsor Pharmaceuticals
Windsor Pharmaceuticals SA is a relatively new pharmaceutical company focused on the distribution and commercialization of gynecological therapies and devices in Latin American countries. Windsor's leadership counts on a team of experienced former big-pharma country managers with a proven track record in Women's Healthcare. In the coming years, Windsor expects to collaborate closely with Easton Pharmaceuticals/BMV Medica and expand its footprint and product portfolio across an increasing number of Latin American countries.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing medical drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has partnered with BMV Medica S.A. and together own the exclusive distribution rights in Mexico and Latin America for two patented women's diagnostic products and a novel natural treatment for Bacterial Vaginosis. In addition a generic cancer drugs line is being developed for sale in Mexico. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs and Cannabidiol extracts. Easton has closed on an agreement with Ontario based Alliance Group to acquire a 50% property ownership interest and a 20% to 70% ownership interest in 2 businesses, one of which includes the cultivation and distribution of medical / recreational marijuana. Easton has closed on an agreement to acquire 100% of iBliss Inc., a leading e-liquid vapor producer and distributor with international sales
For More Information On Easton and Affiliated and Partner Company's Visit:
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
CONTACT INFORMATION Evan Karras / CEO / President Tel: +1(416) 619-0291 Tel: +1(347) 284-0192 Email: firstname.lastname@example.org